Tsfg LLC Buys 6,734 Shares of AbbVie Inc. $ABBV

Tsfg LLC grew its stake in AbbVie Inc. (NYSE:ABBV) by 5.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 134,486 shares of the company’s stock after buying an additional 6,734 shares during the quarter. AbbVie accounts for about 4.3% of Tsfg LLC’s portfolio, making the stock its 4th largest holding. Tsfg LLC’s holdings in AbbVie were worth $33,842,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the stock. Litman Gregory Wealth Management LLC purchased a new position in AbbVie during the fourth quarter valued at approximately $28,000. Imprint Wealth LLC boosted its position in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares in the last quarter. Burk Holdings LLC acquired a new stake in shares of AbbVie during the 2nd quarter worth approximately $30,000. IFC & Insurance Marketing Inc. purchased a new position in shares of AbbVie during the 4th quarter valued at approximately $31,000. Finally, Abound Financial LLC purchased a new position in shares of AbbVie during the 4th quarter valued at approximately $32,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price target on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Wells Fargo & Company upped their price objective on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research report on Monday, August 17th. BNP Paribas Exane raised their target price on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. Morgan Stanley reaffirmed an “overweight” rating and issued a $296.00 price target on shares of AbbVie in a report on Monday, August 3rd. Finally, Barclays raised their price objective on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $275.95.

Insider Transactions at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.

AbbVie Trading Up 0.9%

ABBV stock opened at $251.04 on Thursday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47. The business’s 50-day moving average is $254.66 and its 200 day moving average is $230.55. The stock has a market cap of $443.53 billion, a price-to-earnings ratio of 70.92, a PEG ratio of 1.13 and a beta of 0.29.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.